Selecta had $136.2 million in cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022, as compared to cash, cash equivalents, marketable securities, and restricted cash of $129.4 million as of December 31, 2021. Selecta believes its available cash, cash equivalents, restricted cash, and marketable securities will be sufficient to meet its operating requirements into mid-2024
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SELB:
- Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
- Selecta Biosciences management to meet virtually with Cantor Fitzgerald
- Selecta Biosciences price target lowered to $9 from $10 at Canaccord
- Solid Biosciences appoints Tan as Chief Financial Officer
